WO2003001863A3 - Novel endothelially expressed dnas and proteins, and their use - Google Patents

Novel endothelially expressed dnas and proteins, and their use Download PDF

Info

Publication number
WO2003001863A3
WO2003001863A3 PCT/EP2002/006770 EP0206770W WO03001863A3 WO 2003001863 A3 WO2003001863 A3 WO 2003001863A3 EP 0206770 W EP0206770 W EP 0206770W WO 03001863 A3 WO03001863 A3 WO 03001863A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
nucleic acid
acid sequences
relates
novel
Prior art date
Application number
PCT/EP2002/006770
Other languages
French (fr)
Other versions
WO2003001863A2 (en
Inventor
Sigrid Scheek
Holger Hiemisch
Anthony Lanahan
Jean B Regard
Paul F Worley
Eckart Krupp
Markus Schwaninger
Nauder Faraday
Original Assignee
Axaron Bioscience Ag
Sigrid Scheek
Holger Hiemisch
Anthony Lanahan
Jean B Regard
Paul F Worley
Eckart Krupp
Markus Schwaninger
Nauder Faraday
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axaron Bioscience Ag, Sigrid Scheek, Holger Hiemisch, Anthony Lanahan, Jean B Regard, Paul F Worley, Eckart Krupp, Markus Schwaninger, Nauder Faraday filed Critical Axaron Bioscience Ag
Priority to EP02740735A priority Critical patent/EP1402033A2/en
Priority to AU2002314181A priority patent/AU2002314181A1/en
Priority to US10/482,065 priority patent/US20040260058A1/en
Publication of WO2003001863A2 publication Critical patent/WO2003001863A2/en
Publication of WO2003001863A3 publication Critical patent/WO2003001863A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)

Abstract

The present invention relates to novel, specifically expressed proteins and to nucleic acid sequences or transgenic nucleic acids constructs which encode the proteins. The invention also relates to transgenic organisms or animals which harbor the nucleic acid sequences or recombinant nucleic acid constructs and also to monoclonal or polyclonal antibodies and binding factors which are directed against the isolated proteins. The invention furthermore relates to a process for finding substances which possess specific finding affinity with the proteins according to the invention, and to a process for qualitatively or quantitatively detecting the nucleic acid sequences according to the invention or the proteins according to the invention. The invention furthermore relates to the use of nucleic acid sequences and proteins. The invention also encompasses processes for finding substances which modulate the function of the proteins according to the invention. It also relates to the use of these proteins for producing drugs.
PCT/EP2002/006770 2001-06-27 2002-06-19 Novel endothelially expressed dnas and proteins, and their use WO2003001863A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02740735A EP1402033A2 (en) 2001-06-27 2002-06-19 Novel endothelially expressed dnas and proteins, and their use
AU2002314181A AU2002314181A1 (en) 2001-06-27 2002-06-19 Novel endothelially expressed dnas and proteins, and their use
US10/482,065 US20040260058A1 (en) 2001-06-27 2002-06-19 Novel endothelially expressed dnas and proteins, and their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10130657.1 2001-06-27
DE10130657A DE10130657A1 (en) 2001-06-27 2001-06-27 New endothetially expressed protein and its use

Publications (2)

Publication Number Publication Date
WO2003001863A2 WO2003001863A2 (en) 2003-01-09
WO2003001863A3 true WO2003001863A3 (en) 2003-07-31

Family

ID=7689426

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/006770 WO2003001863A2 (en) 2001-06-27 2002-06-19 Novel endothelially expressed dnas and proteins, and their use

Country Status (5)

Country Link
US (1) US20040260058A1 (en)
EP (1) EP1402033A2 (en)
AU (1) AU2002314181A1 (en)
DE (1) DE10130657A1 (en)
WO (1) WO2003001863A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050832A1 (en) * 2004-12-23 2008-02-28 Buechler Kenneth F Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
AU2006299417A1 (en) * 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in Systemic Inflammatory Response Syndromes
US8221995B2 (en) * 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20090004755A1 (en) * 2007-03-23 2009-01-01 Biosite, Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
EP2617735A3 (en) 2008-12-24 2013-10-16 Rsr Limited Human anti tshr antibodies
US9677042B2 (en) 2010-10-08 2017-06-13 Terumo Bct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
JP6612227B2 (en) 2013-11-16 2019-11-27 テルモ ビーシーティー、インコーポレーテッド Cell growth in bioreactors
CN106232800B (en) 2014-03-25 2020-07-03 泰尔茂比司特公司 Passive replacement of media
EP3198006B1 (en) 2014-09-26 2021-03-24 Terumo BCT, Inc. Scheduled feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CN110452896B (en) * 2019-08-08 2022-08-16 南京农业大学 Plant insect-resistant related proteins OsPAL6 and OsPAL8 as well as coding genes and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038082A2 (en) * 1996-04-04 1997-10-16 Progen Biotechnik Gmbh Hypertonia gene
WO1999018191A1 (en) * 1997-10-02 1999-04-15 Imclone Systems Incorporated Transgenic animals with knocked-in vec receptor genes and uses thereof
WO1999040225A1 (en) * 1998-02-09 1999-08-12 The Johns Hopkins University School Of Medicine Immediate early genes and methods of use therefor
WO2000076309A2 (en) * 1999-06-10 2000-12-21 D.Collen Research Foundation Vzw Non-human transgenic animals deficient in gas6 function and their use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038082A2 (en) * 1996-04-04 1997-10-16 Progen Biotechnik Gmbh Hypertonia gene
WO1999018191A1 (en) * 1997-10-02 1999-04-15 Imclone Systems Incorporated Transgenic animals with knocked-in vec receptor genes and uses thereof
WO1999040225A1 (en) * 1998-02-09 1999-08-12 The Johns Hopkins University School Of Medicine Immediate early genes and methods of use therefor
WO2000076309A2 (en) * 1999-06-10 2000-12-21 D.Collen Research Foundation Vzw Non-human transgenic animals deficient in gas6 function and their use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 1 December 2001 (2001-12-01), TASHIRO ET AL: "NEDO human cDNA sequencing project", XP002219791, retrieved from EMBL Database accession no. Q96LR9 *
DATABASE EMBL [online] 1 March 2001 (2001-03-01), WIEMANN ET AL: "Towards a Catalog of Human Genes and Proteins: Sequencing and Analysis of 500 Novel Complete Protein Coding Human cDNAs", XP002219790, retrieved from EMBL Database accession no. Q9H015 *
DATABASE EMBL [online] 7 April 1999 (1999-04-07), MUZNY ET AL: "Direct Submission", XP002219792, retrieved from EMBL Database accession no. AC007215 *
FROSSARD P M ET AL: "ASSOCIATION BETWEEN A DIMORPHIC SITE ON CHROMOSOME 12 AND CLINICAL DIAGNOSIS OF HYPERTENSION IN THREE INDEPENDENT POPULATIONS", CLINICAL GENETICS, COPENHAGEN, DK, vol. 48, no. 6, 1 December 1995 (1995-12-01), pages 284 - 287, XP002043529 *
HORREVOETS A J G ET AL: "VASCULAR ENDOTHELIAL GENES THAT ARE RESPONSIVE TO TUMOR NECROSIS FACTOR-ALPHA IN VITRO ARE EXPRESSED IN ATHEROSCLEROTIC LESIONS, INCLUDING INHIBITOR OF APOPTOSIS PROTEIN-1, STANNIN, AND TWO NOVEL GENES", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 93, no. 10, 15 May 1999 (1999-05-15), pages 3418 - 3431, XP002936412, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
WO2003001863A2 (en) 2003-01-09
EP1402033A2 (en) 2004-03-31
US20040260058A1 (en) 2004-12-23
DE10130657A1 (en) 2003-01-16
AU2002314181A1 (en) 2003-03-03

Similar Documents

Publication Publication Date Title
WO2003001863A3 (en) Novel endothelially expressed dnas and proteins, and their use
IL188094A0 (en) Il-1?? binding antibodies and fragments thereof
HK1142272A1 (en) Specific binding proteins and uses thereof
WO2003000842A3 (en) Novel proteins and nucleic acids encoding same
DK2020604T3 (en) Ligand for the G protein-coupled receptor FPRL2
WO2002020569A3 (en) Mammalian genes; related reagents and methods
WO2003087129A3 (en) Immunogenic peptides, and method of identifying same
WO2001036641A3 (en) DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO
WO2002081498A3 (en) Novel proteins and nucleic acids encoding same
WO2003010327A3 (en) Novel proteins and nucleic acids encoding same
WO2009086125A3 (en) Affinity tag nucleic acid and protein compositions, and processes for using same
WO2002036773A3 (en) Nod2 nucleic acids and proteins
WO2002042458A3 (en) G protein coupled receptors
WO2002072757A3 (en) Novel proteins and nucleic acids encoding same
WO2002000719A3 (en) Human and mouse g-protein couipled receptors
WO2002033084A3 (en) Identification of the dombrock blood group glycoprotein as a polymorphic member of the adp-ribosyltransferase gene family
EP0816498A3 (en) Excitatory amino acid receptor protein and related nucleic acid compounds
WO2003004678A3 (en) Novel receptors
WO2001081623A3 (en) Neuronally expressed protein having apoptotic activity, and use thereof
WO2001085989A3 (en) Hypha-specific factors from candida albicans
WO2002022681A3 (en) Neuronally expressed protein and use thereof
WO2001059114A3 (en) Tumor suppressor gene, p47ing3
WO2001061001A3 (en) Novel, central nervous protein, that modulates k+ flows
WO2001021794A3 (en) Smad associating polypeptides
WO2003048320A3 (en) Novel motor protein of p. falciparum and methods for its use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002740735

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004108122

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2002740735

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10482065

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2002740735

Country of ref document: EP